Dynavax Technologies (DVAX) Projected to Post Quarterly Earnings on Thursday

Dynavax Technologies (NASDAQ:DVAX) is anticipated to post its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect Dynavax Technologies to post earnings of $0.08 per share for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 19, 2026 at 4:30 PM ET.

Dynavax Technologies Price Performance

Shares of NASDAQ:DVAX opened at $15.50 on Thursday. Dynavax Technologies has a 52-week low of $9.20 and a 52-week high of $15.73. The stock has a market cap of $1.82 billion, a P/E ratio of -41.89 and a beta of 0.97. The business has a fifty day moving average of $14.21 and a two-hundred day moving average of $11.75. The company has a quick ratio of 6.94, a current ratio of 7.62 and a debt-to-equity ratio of 0.41.

Insider Buying and Selling

In other Dynavax Technologies news, COO David F. Novack sold 114,000 shares of Dynavax Technologies stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $15.64, for a total value of $1,782,960.00. Following the completion of the transaction, the chief operating officer directly owned 63,344 shares of the company’s stock, valued at $990,700.16. The trade was a 64.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 2.98% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in DVAX. Picton Mahoney Asset Management acquired a new position in shares of Dynavax Technologies in the fourth quarter valued at approximately $1,870,000. Vise Technologies Inc. grew its stake in shares of Dynavax Technologies by 31.9% in the fourth quarter. Vise Technologies Inc. now owns 30,722 shares of the biopharmaceutical company’s stock worth $473,000 after acquiring an additional 7,431 shares in the last quarter. CIBC Asset Management Inc purchased a new stake in shares of Dynavax Technologies during the fourth quarter worth $162,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in shares of Dynavax Technologies by 76.1% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 44,710 shares of the biopharmaceutical company’s stock valued at $688,000 after acquiring an additional 19,325 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its holdings in Dynavax Technologies by 3,193.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 3,129 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 3,034 shares during the period. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. William Blair cut shares of Dynavax Technologies from an “outperform” rating to a “hold” rating in a research report on Wednesday, December 24th. Wall Street Zen upgraded shares of Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 27th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Dynavax Technologies in a report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Dynavax Technologies currently has a consensus rating of “Hold” and an average target price of $24.33.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.